BACKGROUND: Racial and ethnic minorities are disproportionately affected by diabetes and at greater risk of experiencing poor diabetes-related outcomes compared with non-Hispanic whites. The Affordable Care Act (ACA) was implemented to increase health insurance coverage and reduce health disparities. OBJECTIVE: Assess changes in diabetes-associated biomarkers [hemoglobin A1c (HbA1c) and low-density lipoprotein] 24 months pre-ACA to 24 months post-ACA Medicaid expansion by race/ethnicity and insurance group. RESEARCH DESIGN: Retrospective cohort study of community health center (CHC) patients. SUBJECTS: Patients aged 19-64 with diabetes living in 1 of 10 Medicaid expansion states with ≥1 CHC visit and ≥1 HbA1c measurement in both the pre-ACA and the post-ACA time periods (N=13,342). METHODS: Linear mixed effects and Cox regression modeled outcome measures. RESULTS: Overall, 33.5% of patients were non-Hispanic white, 51.2% Hispanic, and 15.3% non-Hispanic black. Newly insured Hispanics and non-Hispanic whites post-ACA exhibited modest reductions in HbA1c levels, similar benefit was not observed among non-Hispanic black patients. The largest reduction was among newly insured Hispanics versus newly insured non-Hispanic whites (P<0.05). For the subset of patients who had uncontrolled HbA1c (HbA1c≥9%) within 3 months of the ACA Medicaid expansion, non-Hispanic black patients who were newly insured gained the highest rate of controlled HbA1c (hazard ratio=2.27; 95% confidence interval, 1.10-4.66) relative to the continuously insured group. CONCLUSIONS: The impact of the ACA Medicaid expansion on health disparities is multifaceted and may differ across racial/ethnic groups. This study highlights the importance of CHCs for the health of minority populations.
BACKGROUND: Racial and ethnic minorities are disproportionately affected by diabetes and at greater risk of experiencing poor diabetes-related outcomes compared with non-Hispanic whites. The Affordable Care Act (ACA) was implemented to increase health insurance coverage and reduce health disparities. OBJECTIVE: Assess changes in diabetes-associated biomarkers [hemoglobin A1c (HbA1c) and low-density lipoprotein] 24 months pre-ACA to 24 months post-ACA Medicaid expansion by race/ethnicity and insurance group. RESEARCH DESIGN: Retrospective cohort study of community health center (CHC) patients. SUBJECTS: Patients aged 19-64 with diabetes living in 1 of 10 Medicaid expansion states with ≥1 CHC visit and ≥1 HbA1c measurement in both the pre-ACA and the post-ACA time periods (N=13,342). METHODS: Linear mixed effects and Cox regression modeled outcome measures. RESULTS: Overall, 33.5% of patients were non-Hispanic white, 51.2% Hispanic, and 15.3% non-Hispanic black. Newly insured Hispanics and non-Hispanic whites post-ACA exhibited modest reductions in HbA1c levels, similar benefit was not observed among non-Hispanic black patients. The largest reduction was among newly insured Hispanics versus newly insured non-Hispanic whites (P<0.05). For the subset of patients who had uncontrolled HbA1c (HbA1c≥9%) within 3 months of the ACA Medicaid expansion, non-Hispanic black patients who were newly insured gained the highest rate of controlled HbA1c (hazard ratio=2.27; 95% confidence interval, 1.10-4.66) relative to the continuously insured group. CONCLUSIONS: The impact of the ACA Medicaid expansion on health disparities is multifaceted and may differ across racial/ethnic groups. This study highlights the importance of CHCs for the health of minority populations.
Authors: Julienne K Kirk; Leah V Passmore; Ronny A Bell; K M Venkat Narayan; Ralph B D'Agostino; Thomas A Arcury; Sara A Quandt Journal: Diabetes Care Date: 2007-10-31 Impact factor: 19.112
Authors: Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson; Karen M Eddleman; Nicole M Jarrett; Ken LaBresh; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli Journal: Circulation Date: 2013-11-12 Impact factor: 29.690
Authors: Brigit Hatch; Miguel Marino; Marie Killerby; Heather Angier; Megan Hoopes; Steffani R Bailey; John Heintzman; Jean P O'Malley; Jennifer E DeVoe Journal: J Gen Intern Med Date: 2017-04-03 Impact factor: 5.128
Authors: Gregory A Nichols; Jay Desai; Jennifer Elston Lafata; Jean M Lawrence; Patrick J O'Connor; Ram D Pathak; Marsha A Raebel; Robert J Reid; Joseph V Selby; Barbara G Silverman; John F Steiner; W F Stewart; Suma Vupputuri; Beth Waitzfelder Journal: Prev Chronic Dis Date: 2012-06-07 Impact factor: 2.830
Authors: Catherine C Gao; Nataly R Espinoza Suarez; Freddy J K Toloza; Ariana S Malaga Zuniga; Sarah R McCarthy; Kasey R Boehmer; Lixia Yao; Sunyang Fu; Juan P Brito Journal: Mayo Clin Proc Innov Qual Outcomes Date: 2021-09-17
Authors: Jordan Gemelas; Miguel Marino; Steele Valenzuela; Teresa Schmidt; Andrew Suchocki; Nathalie Huguet Journal: BMJ Open Diabetes Res Care Date: 2021-12